Popular Articles

Response To Healthcare For London Consultation Results
Joe Korner, Director of Communications at The Stroke Association said:
generic viagra online
Yissum Signs A Collaboration Agreement With Aurum Ventures MKI For The Development Of Breakthrough Liver-Bypassing Oral Drug Delivery Nanotechnology
Yissum Research Development Company Ltd., the Technology Transfer Company of the Hebrew University of Jerusalem, announced today at the ILSI-Biomed Israel 2009 conference, it has signed an agreement with Aurum, Ventures MKI, the technology investment arm of Mr. Morris Kahn, for the development of a nanotechnology controlled release drug delivery platform that increases the bioavailability of orally administered lipophilic drugs. The technology was developed by Prof. Simon Benita at the Hebrew University"s School of Pharmacy.
News of the day
Array BioPharma Advances Its Lead MEK Inhibitor Into Cancer
Array BioPharma Inc. (NASDAQ: ARRY) announced the filing of an investigational new drug (IND) application with the U.S. Food and Drug Administration to initiate a Phase 1 clinical trial in cancer patients with its most advanced wholly owned MEK inhibitor, ARRY-162. Recent research confirms that the MEK pathway acts as a central axis in the proliferation of different tumors including melanoma, non-small cell lung, head/neck and pancreatic cancers. Array plans to simultaneously develop ARRY-162 for the treatment of both cancer and inflammatory disease. Array is currently completing a worldwide Phase 2, double-blinded clinical trial with ARRY-162 in 200 patients with active rheumatoid arthritis.
Public Health

Boehringer Ingelheim And The World Stroke Organization Announce Partnership In The World Stroke Academy

Boehringer Ingelheim announced that it will become the founding sponsor of the World Stroke Academy, a novel training initiative for stroke professionals being developed by the World Stroke Organization ( WSO). This latest educational initiative from the WSO will bring together an international group of stroke experts - led by Professor Michael Brainin of the Danube University Krems, Austria - to provide information about stroke and knowledge for health professionals and medical doctors in order to improve prevention, therapy and management of stroke. Professor Bo Norrving, President of the WSO said: "The World Stroke Academy is a project of the World Stroke Organization and aims at improving education on a global scale. It is a platform open to all stroke societies aiming at global effectiveness of fighting stroke and its physical and mental consequences." Dr. Manfred Haehl, Corporate Senior Vice President Medicine, Boehringer Ingelheim said: "Boehringer Ingelheim is committed to patient care and we are proud to support initiatives that have potential to benefit all patients. Stroke is one of the biggest causes of death and severe disability worldwide, and a great many patients simply don"t have access to specialist care. We hope the World Stroke Academy will contribute to training a new generation of specialists who can help provide that care." The World Health Organization estimates that 5.7 million people in the world die each year from stroke.1 Among survivors, 40% experience moderate to severe disability and 10% require institutional care. 2 The World Stroke Academy aims to provide a mixture of online and conventional activities to educate and help facilitate training of stroke professionals across all regions of the world. Key objectives of the initiative include: - Promoting knowledge and education on stroke management on a global level according to the WSO mission statement - Improving and standardising educational standards in primary and secondary stroke prevention, acute management and rehabilitation - Leveraging guidelines to ensure best practice is implemented within all regions of the world - Further developing the WSO as a leading global educator. References 1. Cardiovascular diseases. Fact sheet N°317. February 2007. WHO. http://https://www.who.int/mediacentre/factsheets/fs317/en/ 2. National Institute of Neurological Disorders and Stroke. Stroke Rehabilitation Information. Boehringer Ingelheim


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):